Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | |
| Sales | 5,716 | 4,278 | 176 | 0 |
| Gross Profit | 5,716 | 4,278 | 176 | N/A |
| Operating Expenses | 49,188 | 36,542 | 25,233 | 4,222 |
| Operating Income | -43,472 | -32,264 | -25,057 | -4,222 |
| Interest Expense | 969 | 661 | 127 | 0 |
| Other Income | 1,527 | 271 | 151 | 86 |
| Pre-tax Income | -42,914 | -32,654 | -25,033 | -4,136 |
| Net Income Continuous | -42,914 | -32,654 | -25,033 | -4,136 |
| Net Income | $-42,914 | $-32,654 | $-25,033 | $-4,136 |
| EPS Basic Total Ops | -1.96 | -2.98 | -29.64 | -14.74 |
| EPS Basic Continuous Ops | -1.96 | -2.75 | -26.55 | -12.50 |
| EPS Diluted Total Ops | -1.96 | -2.98 | -29.64 | -14.74 |
| EPS Diluted Continuous Ops | -1.96 | -2.75 | -26.55 | -12.50 |
| EBITDA(a) | $-40,490 | $-29,820 | $-24,219 | $-4,186 |